| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.48 M USD | 357903 USD | -4.67 M USD | -1.54 M USD | 954170 USD | 1.32 M USD | 233511 USD | -373404 USD | 1.18 M USD | -323902 USD | 2.90 M USD | 302364 USD |
| Depreciation & Amortization | 2.78 M USD | 2.73 M USD | 2.70 M USD | 2.47 M USD | 2.44 M USD | 2.33 M USD | 2.25 M USD | 1.50 M USD | 885331 USD | 783275 USD | 525918 USD | 446045 USD |
| Stock-Based Compensation | 295871 USD | 325551 USD | 368866 USD | 266244 USD | 144313 USD | 253135 USD | 313144 USD | 344016 USD | 199783 USD | 67399 USD | 23222 USD | 30004 USD |
| Capital Expenditures | 1.25 M USD | 465725 USD | 1.89 M USD | 3.98 M USD | 2.61 M USD | 4.07 M USD | 1.39 M USD | 2.03 M USD | 17.76 M USD | 3.59 M USD | 2.72 M USD | 1.54 M USD |
| Cash Flow from Investing | -1.21 M USD | -461225 USD | -1.89 M USD | -3.96 M USD | -1.60 M USD | -2.57 M USD | -3.40 M USD | -1.79 M USD | -12.27 M USD | -4.42 M USD | -4.62 M USD | -1.54 M USD |
| Cash Flow from Financing | -1.21 M USD | 2.88 M USD | 1.75 M USD | 1.11 M USD | 3.88 M USD | 1.91 M USD | 6.94 M USD | 889615 USD | 9.75 M USD | 8.32 M USD | 2.44 M USD | -187163 USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 1.22 M USD | -107822 USD | -6.57 M USD | -5.52 M USD | -1.65 M USD | -2.76 M USD | -1.16 M USD | -2.40 M USD | -16.58 M USD | -3.91 M USD | 181047 USD | -1.23 M USD |
ImmuCell Corporation is a biotechnology company engaged in the development, manufacture, and sale of products that improve animal health and productivity in the dairy and beef industries. The company's primary focus is on the development of products that provide alternatives to traditional antibiotics, offering innovative solutions to enhance the immune system of livestock. ImmuCell’s notable product, First Defense, helps prevent scours (diarrhea) in newborn dairy and beef calves, a common ailment that can impair growth and development and lead to high mortality rates. By addressing such pervasive health challenges in the livestock sector, ImmuCell significantly impacts agricultural productivity and sustainability. Located in the United States, ImmuCell Corporation contributes to the broader biotechnology and agricultural markets by promoting healthier livestock, thereby potentially reducing the dependency on antibiotics and aligning with global trends towards more sustainable and responsible farming practices. This focus not only underscores the company’s role in animal health innovation but also highlights its importance in food safety and the agricultural supply chain.